Investing.com - Krystal Biotech reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Krystal Biotech announced earnings per share of $-1.17 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-1.19 on revenue of $200K.
Krystal Biotech shares are down 11% from the beginning of the year and are trading at $74.61 , down-from-52-week-high.
Krystal Biotech shares gained 1.91% in intra-day trade the report.
Krystal Biotech follows other major Healthcare sector earnings this month
Krystal Biotech's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar